Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03048695
Other study ID # 150601
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 18, 2017
Est. completion date December 31, 2020

Study information

Verified date February 2021
Source Sykehuset Innlandet HF
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

About 85% of patients with schizophrenia have cognitive impairments, executive functions being particularly affected. Executive dysfunction, and cognitive deficits in general, are important predictors of functional outcomes, including social problem solving, activities of daily living, life satisfaction, and the ability to return to work or school.The main objective of the current study is to examine the efficacy of group-based Goal Management Training (GMT) for patients with broad schizophrenia spectrum disorders or high risk individuals with executive deficits. The short term goals are to investigate whether GMT can improve participants' ability to organize and achieve goals in everyday life in addition to improving aspects of emotional health. A long-term goal would be to establish an evidence base for nonpharmacological interventions for patients with broad schizophrenia spectrum disorders or high risk for schizophrenia. Main research questions: (1) Does a RCT with GMT delivered to patients with broad schizophrenia spectrum disorders or high risk for schizophrenia result in improved executive functioning, measured by self-reported and/or objective measures of executive functions? (2) Does GMT result in improved goal attainment in everyday life, social- and real world functioning? (3) Does GMT have a positive impact on the patients' emotional health? (4) Are there specific characteristics in patients with broad schizophrenia spectrum disorders or high risk for schizophrenia that are associated with better treatment benefit from GMT?


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 16 Years to 67 Years
Eligibility Inclusion Criteria: - Being consecutively referred to treatment for a DSM-IV diagnosis of broad schizophrenia spectrum psychosis (schizophrenia, schizophreniform disorder and schizoaffective disorder) or high risk for psychosis or being treated for psychotic disorder for less than 5 years. - Reporting executive problems through (a) structured interview, or (b) self-report, i.e. BRIEF scale T-score < 55. Exclusion Criteria: - Reported ongoing alcohol or substance abuse. - Premorbid neurological disease or insult and/or comorbid neurological disease. ° Severe cognitive problems interfering with the capacity to participate. - IQ below 70.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
GMT
Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance

Locations

Country Name City State
Norway Sykehuset Innlandet Reinsvoll Reinsvoll

Sponsors (2)

Lead Sponsor Collaborator
Sykehuset Innlandet HF University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Behavior Rating Inventory for Executive Functions Assessing change Baseline, immediately post-intervention and 6 months follow-up
Primary Conners Continuous Performance Test III Assessing change Baseline, immediately post-intervention and 6 months follow-up
Primary Positive and Negative Syndrome Scale Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Global Assessment of Functioning-Split Version Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary The Hotel Task Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Delis Kaplan Executive Function System (D-KEFS) subtests Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Digit span and Letter-number sequencing Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Iowa Gambling Task Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Dysexecutive Questionnaire (self-and informant) Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Cognitive Failures Questionnaire Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Goal Attainment Scaling Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Everyday Functioning from NORMENT Long time follow up questionnaires Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary General Perceived Self-Efficacy Scale Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Social Functioning Scale Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary The Perceived Quality of Life Scale Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Rosenberg self-esteem scale Assessing change Baseline, immediately post-intervention and 6 months follow-up
Secondary Hopkins Symptom Checklist 10 Assessing change Baseline, immediately post-intervention and 6 months follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A